Discovers and develops therapeutic antibodies for cancer and autoimmune diseases. Commercializes Tafasitamab (Monjuvi/Minjuvi) for the treatment of B-cell malignancies. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 35% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 10.3× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 35% a year on average.
Sales run at $276.5M a year. A small number, but proof the product has real buyers.
There is $792.2M in the vault; even if every debt were paid off, $54.3M would remain.
A loss of $220.1M against $276.5M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.